Index

5-HT see serotonin
absolute/relative risk measures, RCTs 27, 41
academic psychiatry
conflicts of interest 33–40, 42–4, 52–4
critique 39–40, 42–4
fees 34–41, 52–4
ghostwriting concerns 34–5
pharmaceutical industry 31–40, 42–4
ACE inhibitors, hypertension 8, 46
acetyl salicylic acid 19, 46
see also aspirin
acetylcholine (ACh) 12–17
addictions 14, 23, 80, 82–3, 92, 102–3, 106
ADHD see attention-deficit hyperactivity disorder
administration routes
antipsychotics 68
lithium 36–7
adolescents
see also children
antidepressants 114–16
bipolar disorder 38, 77–8, 116–21
concepts 109–21
endocrine activity during puberty 114, 115
parent training 120–1
self-harm 115–16
stimulants 109–21
suicidal thoughts 114, 115–16
adult types of ADHD 113–14
see also attention-deficit...
advertisements
pharmaceutical industry 45–7, 49–50, 66
side effects 45–6
to the public 49–50, 66
affective instability (AI)
see also mood...
concepts 69–70, 78–80, 158
definition 69–70, 78–9
‘aggressive’ treatments 124–5, 126, 153, 156
see also polypharmacy
AI see affective instability
alcoholism
see also substance abuse
calories 13, 147, 151
prevalence 151
alprazolam, concepts 106
alternatives to drugs
see also psychotherapy
concepts 30, 53–4, 80, 99, 102, 120–1, 129, 133–42, 159–60, 162–3
selection issues 136–7
American Journal of Psychiatry 29
American Psychiatric Association (APA) 17–18, 29, 35–6, 48, 52, 57, 86, 103, 145, 149
see also DSM...
conflicts of interest 35–6
pharmaceutical industry influences 35–6, 52
amphetamine 3, 5, 109–10
amygdala
see also limbic system
concepts 15
anesthesia 6, 8
animal testing, concepts 25–6
anorexia nervosa
see also eating disorders
concepts 19
anticholinergic side effects 90–1
anticonvulsant mood stabilizers
see also antimanics; bipolar disorder;
carbamazepine; lamotrigine; lithium;
valproate
concepts 9, 70–84, 126, 155–6

The Use and Misuse of Psychiatric Drugs: An Evidence-Based Critique  by Joel Paris
© 2010 John Wiley & Sons, Ltd
INDEX

anticonvulsant mood stabilizers (Cont.)
critique 71–3
historical background 9, 70–1
‘antidepressant tolerance’ 28
see also placebo effects
antidepressants 6–10, 14–15, 19, 20, 28, 38,
40–1, 53–4, 66, 72–3, 85–107, 114–16,
124–6, 128, 135–42, 143, 145–53, 155–63
see also anxiolytics . . . ; depression; lithium;
monoamine oxidase inhibitors; mood
stabilizers; tricyclics
augmentation/switching approaches 98–102,
124–5, 130, 135–6, 152, 162–3
bipolar disorder 72–3, 76–7
children 114–16
clinical conclusions 107
clinical guidelines 102–3
‘cosmetic psychopharmacology’ 152–3
critique 89–90, 93–107, 158–62
definition 85
effectiveness 85–107
historical background 6–7, 8, 9, 10, 90–3
new synapses 15
non-SSRI antidepressants 92–3
OCD 14, 85, 105–6
recurrence-prevention issues 90, 161
relapse issues 95–7
selection issues 97–8, 162–3
sexual side effects 92–3
side effects 90–107
spectrum of action 85
SSRIs 9, 15, 43, 68, 90–7, 115–16, 125, 161
suicidal thoughts 43, 86–7, 88, 91, 103–4
antihistamines, concepts 6, 7
antimanic
see also anticonvulsant mood stabilizers;
lithium; mania; mood . . .
concepts 7–8, 9, 10, 69–84
definition 69–70
historical background 7–8, 9, 10
antineurotics
see also antidepressants
concepts 85
‘antipsychiatry’, concepts 158–62
antipsychotics 6–9, 13, 20, 57–68, 72, 101–2,
119–20, 125–6, 155, 158, 161–3
see also chlorpromazine; haloperidol;
neuroleptics; psychosis
administration routes 68
atypical (second-generation) antipsychotics 9,
13–14, 60–8, 72, 120–1
bipolar disorder 64–7, 70, 72, 119–20
critique 57–68, 158, 161
depression 64–8, 101–2, 125–6
effectiveness 8, 10, 13–14, 57–68
FGAs 6–7, 9, 58–60, 62–8
historical background 6–7, 8
mood disorders 64–7, 69
off-label approaches 57–8, 61–2, 66, 68, 163
side effects 58–68, 120
antisocial personality disorder
see also conduct disorder; psychopathy
concepts 117–18
anxiety 3–5, 19, 32, 58, 67–8, 85, 93, 105–6,
115, 134, 135–63
see also obsessive-compulsive . . . ; panic . . .;
post-traumatic stress . . .
medicalization of distress 143–4, 146, 155–63
treatments 3–4, 5, 19, 32, 58, 68, 85, 93, 134,
135–63
anxiolytics (tranquilizers)
see also antidepressants; benzodiazepines;
diazepam; meprobamate
concepts 7, 8, 14–15, 105–7, 125, 126–5, 163
historical background 7, 8
approval processes for new drugs, concepts
33–4, 41–2, 53–4
apiprazole 50
aripiprazole, concepts 62, 66–7
aspartate 12–17
aspirin 19, 46
see also acetyl salicylic acid
assessments of new drugs, standards 10
atomoxetine, concepts 110
attention-deficit hyperactivity disorder (ADHD)
adult types 113–14
biological markers 110–11, 114
comorbidities 110–14, 116–20
concepts 38, 82, 109–14, 116–20, 145
definition 111–12
diagnoses 110–14, 116–20, 145
diagnostic boundaries 110–11, 113
social dimension 112–13
symptoms 110–14, 116–20
treatments 38, 82, 109–14, 116–20
atypical (second-generation) antipsychotics
concepts 9, 13–14, 60–8, 72, 120–1
critique 62–4, 68, 72–3, 120–1
historical background 9, 60–2
metabolic syndrome 62, 68
tardive dyskinesia 60, 64, 68, 120
augmentation/switching approaches,
treatment-resistant depression 98–102,
124–5, 130, 135–6, 152, 162–3
INDEX 197

availability bias, concepts 20
avoiding-illness market 31–2, 153
barbiturates 3, 4–5, 83, 155
BDNF see brain-derived neurotrophic factor
behaviors, neurotransmitters 11–17, 92–3, 114–15, 127–8, 139–40
Bentall, Richard 161
benzodiazepines
see also anxiolytics . . . ; chlorazepoxide; diazepam
care 7, 13, 68, 105–7, 125
effectiveness 105–7
historical background 7
side effects 106–7
Biederman, Joseph 38
‘Big Pharma’ see pharmaceutical industry
biological markers
ADHD 110–11, 114
depression 87–8
mental illness 80–1, 87–8, 110–11, 114, 119
bipolar disorder
see also anticonvulsant . . . ; lithium; mania; mood . . .
antidepressants 72–3, 76–7
antipsychotics 64–7, 70, 72, 119–20
causes 10, 72–3
children and adolescents 38, 77–8, 116–21
care 7, 10, 19, 38, 50, 69–84, 116–21,
125–6, 146, 157, 158, 160, 161
definition 73–8, 119–20
diagnoses 19, 73–6, 77–8, 80–4, 116–21
diagnostic boundaries 78–83, 116–21
diagnostic/treatment fads 77–8, 82–4
drug advertisements 50, 66
family histories 80–1, 119
follow-up studies 71–3
forms 73–8
moodiness distinctions 74–5, 77–8, 82–4
onset 119–20
personality disorders 79, 82–3
schizophrenia 73, 75
’soft’/‘hard’ concepts 77–8, 81, 119–20
spectrum 71–2, 73–8, 81–2, 117–20
statistics 81–3
suicide attempts 70–1
symptoms 73–6, 116–21
treatment-resistance problems 10, 66–7
treatments 7, 10, 38, 50, 64–7, 69–84, 116–21,
125–6, 157, 158, 160, 161
bipolar I disorder, concepts 71–2, 73–8, 81–2, 119–20
bipolar II disorder, concepts 71–2, 73–8, 79–80, 81–2, 119–20
bipolar III disorder, concepts 73, 76–8
bipolar IV disorder, concepts 76–8, 79
bipolar imperialism, definition 83
borderline personality disorder
see also affective instability
concepts 79, 85, 126
the brain, concepts 11–17, 92–3, 114–15, 127–8, 139–40, 153, 155–6
brain-derived neurotrophic factor (BDNF),
concepts 15
breast cancer 22
Brown University 38
bulimia nervosa 95, 135
see also eating disorders
buspirone, concepts 93, 99–102, 110
bupropion, concepts 93, 100–2
butyrophenones
see also haloperidol
historical background 6–7
Cade, John (1912–1980) 7
Canada 40, 43–4, 50, 52, 137, 139, 145–6, 149
capitalism 33
carbamazepine
see also anticonvulsant mood stabilizers
concepts 71–2
cardiocirculatory diseases 46
Carré, John le 42, 44
case reports, critique 23
catatomias 4
CATIE 63–4
causes of mental illness 10, 11–12, 13–17, 18–19, 127–8, 148–50
CBT see cognitive behavioral therapy
CD see conduct disorder
‘chemical imbalance’ 12–13
children
ADHD 38, 82, 109–14, 116–20, 145
antidepressants 114–16
bipolar disorder 38, 77–8, 116–21
concepts 38, 52, 77–8, 109–21, 145
diagnostic/treatment fads 77–8, 113–14, 120–1, 145
diabetic activity during puberty 114, 115
externalizing disorders 111–14
internalizing disorders 111–14
over-prescription dangers 113–14, 120–1, 145
parent training 120–1
<table>
<thead>
<tr>
<th>INDEX</th>
</tr>
</thead>
</table>
INDEX 199

diagnoses 18–19, 51–2, 86–107, 114–16, 143–53
diagnostic/treatment fads 86–7, 107, 152, 155, 162–3
ECT 3, 4, 5, 7, 8, 88, 102, 104–5, 133
effects 86–7, 107, 152, 155, 162–3
false-positive diagnoses 87–8, 143–4, 147, 152
medicalization of distress 143–53, 155–63
mood stabilizers 126
placebo effects 28, 90, 94–7, 100–2, 115, 161
prevalence 151–2
psychotherapy 89–90, 95–6, 100, 115, 133–42, 159–60
STAR*D effectiveness study 66, 98–102, 135, 162
suicidal thoughts 43, 86–7, 88, 91, 103–4
symptoms 26, 67, 86–107, 114–16
talking therapies 9, 134–42, 159–60
treatment-resistance problems 10, 19, 28, 66–7, 98–103, 152, 162–3
treatments 3–10, 28, 29, 32, 37–8, 54, 64–8, 85–107, 114–16, 125–6, 133–42, 155–63
unhappiness distinctions 87–8, 143–4, 147, 152–3, 155
unitary theory 89–90
diabetes 62
diagnoses
see also clinical judgments; DSM . . . ; symptoms
ADHD 110–14, 116–20, 145
bipolar disorder 19, 73–6, 77–8, 80–4, 116–21
boundaries 78–83, 110–11, 113, 116–21, 143–53
cognitive biases 20
concepts 17–22, 50–4, 77, 143–53
depression 18–19, 51–2, 86–107, 114–16, 143–53
false-positive diagnoses 87–8, 143–4, 147, 152
medicalization of distress 51, 143–53
new disorders 50–2
pharmaceutical industry 50–4, 143–4, 146–7
phenomenological approach 18, 83
schizophrenia 19, 75
timescales 77, 86–7, 152
treatment guides 147–52
diagnostic/treatment fads 77–8, 82–4, 86–7, 107, 113–14, 120–1, 145, 152, 155, 162–3
diazepam see also benzodiazepines
concepts 7, 106
direct brain stimulation, concepts 133
‘disease mongering’ allegations, pharmaceutical industry 143–4
diseases, concepts 17–20
distress, medicalization trends 51, 143–53
diuretics, hypertension 8, 46
dopamine (DA) 12–17
dropouts, RCTs 24, 67
drugs and the brain 11–17, 114–16, 127–8, 139–40, 153–6
DSM series see also American Psychiatric Association
‘Chinese menu approach’ 148
comorbidity issues 148–9
concepts 17–20, 50–2, 73, 74, 81–2, 86–9, 110–11, 113, 145–9
critique 145–9
DSM-III 88–9
DSM-IV-TR 18–19, 51–2, 73, 81–2, 86–8, 110–11, 113, 149–50
DSM-V 52, 74, 150
new mental disorders 50–2, 145–7
dualism 15, 126
duloxetine, concepts 92–3
dysthymia see also depression
concepts 88–9, 103
eating disorders see also anorexia . . . ; bulimia . . .
concepts 80, 82–3, 85
treatments 80, 85
EBM see evidence-based medicine
ECT see electroconvulsive therapy
effect sizes, RCTs 27–8, 98
effectiveness studies
concepts 25, 27–8, 63–4, 66, 98–102, 133–4, 135–6, 159–60
psychotherapy 133–4, 136, 159–60
efficacy studies
concepts 24–5, 26–30, 45–6
psychotherapy 53–4, 80, 95–6, 100, 112, 115, 133–4, 136, 159–60
Eisenberg, Leon 44
electroconvulsive therapy (ECT)
concepts 3, 4, 5, 7, 8, 88, 102, 104–5, 133
effectiveness 3, 5, 8, 88, 102, 104–5, 133
historical background 3, 4, 5, 7, 8
reluctance to prescribe 5, 104–5
scandals 5
INDEX

Eli Lilly 43
Elliot, Carl 152
Emory University 36–7
emotions, limbic system 15
empathy skills 134, 142, 163
endocrine activity during puberty 114, 115
endophenotypes 16, 17, 80–1
environmental factors
affective instability 69–70, 78–80
epiphenetics 16–17, 140–1
stress-diathesis models 140–1
epigenetics, concepts 16–17, 140–1
EPS see extrapyramidal syndrome
erectile dysfunction 50, 147
escitalopram, concepts 97–8
ethics, placebo trials 26
evidence-based medicine (EBM)
see also meta-analyses; randomized clinical trials; systematic reviews
concepts 5, 8, 10, 20–30, 40–2, 47, 133–4, 137–8, 141–2, 155–63
definition 21
historical background 8, 21–3
integrity threats to clinical trials 40–2
principles 22–6
exercise benefits, depression 133
extended-release ploy, generic drugs 47, 62, 66
externalizing disorders in children, concepts 111–14
extrapyramidal syndrome (EPS), concepts 58–9, 61, 63–4
false-positive diagnoses 87–8, 143–4, 147, 152
family histories, bipolar disorder 80–1, 119
fatigue treatments 3
FDA see Food and Drug Administration
fees
see also profits
academic psychiatry 34–41
psychiatrists 44–5, 48–9, 52–4
FGAs see first-generation antipsychotics
first-generation antipsychotics (FGAs)
concepts 6–7, 9, 58–60, 62–8
effectiveness 62–4
historical background 6–7, 9, 58–60
first-order Schneiderian symptoms 75
Fleming, Alexander (1881–1955) 11
fluctuating disease processes 20–1
fluoxetine, concepts 92–3
fluphenazine 59
follow-ups 24, 67, 71–3, 118–20, 135
Food and Drug Administration (FDA) 41, 62, 66, 71–2, 103–4, 148
Foucault, Michel 159
foxglove 11
France 82
Freud, Sigmund (1856–1939) 87
future prospects for psychopharmacology 3–4, 10, 155–63
GABA see gamma aminobutyric acid
gabapentin, concepts 47, 71–2
gamma aminobutyric acid (GABA), concepts 12–17, 106
generic drugs
concepts 47, 62, 66, 98, 106
pharmaceutical industry tricks 47, 62, 66
prescription rates 47, 98
genome, concepts 16–17
ghostwriting concerns, pharmaceutical industry 34–5
gifts, pharmaceutical industry 48–9, 54
glutamate 12–17
glycine 12–17
Goodwin, Fred 38–9
grandiosity 118–19
Grassley, Charles 35–8
Greenberg, Roger 161
grief 147, 152
growth hormone treatments for shortness 147
guanfacine 110
hallucinations
see also schizophrenia
concepts 20, 57–68
haloperidol
see also antipsychotics; butyrophenones
concepts 6–7, 59–60, 68
historical background 6–7, 59–60
side effects 6, 59
HAM-D scores 100
Healy, David 43–4, 103, 160–1
Hippocrates 88
histamine 12–17
history of psychopharmacology 3–10, 21–3
hormone therapy for menopause 147
humanism skills 163
humility needs, treatments 4, 163
Huxley, Thomas 76
‘hype’ problems 10, 15
hyperactive subtype of ADHD, concepts 111–14
hypertension 8, 46, 77, 91, 148
diagnosis 77, 148
treatments 8, 46, 148
hypomania
see also bipolar disorder
concepts 74, 76–84, 117–19
hypotension 58–9
hypothyroidism 70–1
ICD-10 18, 73, 86, 145
see also World Health Organization
ideological factors, psychiatrists 139–41, 155–6
IED see intermittent explosive disorder
imipramine
see also tricyclics
concepts 6, 7, 90
effectiveness 90
impulsive aggression, concepts 14
impulsivity
see also bipolar disorder
concepts 14, 78, 82–4, 85, 157–8
definition 78
in-patient management, historical background 5
inattentive subtype of ADHD, concepts 111–14
industry-funded research
see also pharmaceutical industry
critique 24–5, 28, 29–30, 32–42, 46–7, 52–4
infertility treatments 147
injectable depot neuroleptics, critique 68
insomnia
concepts 3, 58, 86–8, 93, 106–7, 125–6, 150, 152
treatments 3, 58, 106, 125–6
insulin coma therapy 5
integrity threats to clinical trials 40–4
‘intention to treat’ basis analysis, RCTs 24
intermittent explosive disorder (IED), concepts 147, 151
internalizing disorders in children, concepts 111–14
interpersonal psychotherapy (IPT)
see also psychotherapy
effectiveness 9, 134
IPT see interpersonal psychotherapy
irritability
see also bipolar disorder
concepts 74, 78, 82, 88
definition 78
Johnson, Samuel 130
Journal of the American Medical Association 21–2
Keller, Martin 38
‘key opinion-leaders’ (KOLs), concepts 32–9, 44, 45–7
Kirsch, Irving 161
Klein, Donald 19
KOLs see ‘key opinion-leaders’
Kraepelin, Emil (1856–1928) 18, 76–7, 81
Kramer, P. 152
Kuhn, Roland (1912–2005) 7
Laing, RD 159
lamotrigine
see also anticonvulsant mood stabilizers
concepts 71–2
learned helplessness, concepts 26
Lehmann, Heinz 6
lifetime prevalence of mental disorders, statistics 145, 150–2
limbic system
see also amygdala
concepts 15
listening skills 134, 142, 163
lithium
see also antidepressants; antimanic moods; mood stabilizers
concepts 7–8, 9, 10, 36–7, 65, 69–84, 100–2, 126
effectiveness 7, 10, 65, 69–73, 76, 80, 100–2, 126
historical background 7–8, 9, 10, 70
side effects 7, 10, 70–1
suicide attempts 70–1
transdermal patches 36–7
McGill University 5
major depressive disorder
see also depression
concepts 88–107, 143–4, 151, 152, 157
definition 88–90, 143, 151, 152
mania
see also bipolar disorder
antidepressants 72–3
causes 10, 72–3
concepts 4, 5, 7, 10, 20, 57, 64–7, 69–84, 116–21
definition 69–70
treatments 4, 5, 7, 10, 20, 57, 64–7, 69–84
manic depression
see also bipolar disorder
definition 73–4, 76, 81
manipulated results, clinical trials 40–1, 42–4, 45–6
marketing tactics, pharmaceutical industry 10, 15, 45–50, 66–8
media pressures, pharmaceutical industry 35–9, 95
medicalization of distress
anxiety 143–4, 146, 155–63
concepts 51, 143–53, 155–63
definition 143
depression 143–53, 155–63
moralizing attitudes 146–7
pharmaceutical industry 143–4, 146–7, 150
prevalence 145, 150–2
PTSD 144
reasons 144–6
service delivery 153
social attitudes 152–3
values of modern society 31–2, 143, 146–7, 151–3
victim perspectives 143, 146–7, 152–3
Medicines and Healthcare Products Regulatory
Agency (MHRA) 41
melancholia
see also depression
concepts 88, 94, 125–6, 146–7
definition 88
melatonin 12–17
menopause, hormone therapy 147
mental disorders
definitions 146–7, 160
new mental disorders 50–2, 145–50
mental illness
see also diagnoses; symptoms; treatments
biological markers 80–1, 87–8, 110–11, 114, 119
boundaries 78–83, 110–11, 113, 116–21, 143–53
causes 10, 11–12, 13–17, 18–19, 127–8, 140–1, 148–50
definitions 146–7
lifetime prevalence of mental disorders 145, 150–2
medicalization of distress 51, 143–53, 155–63
new disorders 50–2
stigma 144–5, 147, 151, 158–60, 162
meprobamate
see also anxiolytics . . .
concepts 7, 106
historical background 7
side effects 7
meta-analyses 17, 22–30, 40, 63–4, 65–6, 71–2, 90–1, 94–107, 114–15, 120–1, 125–6, 135–6
see also evidence-based medicine
critique 22–3
placebo effects 94–5
metabolic syndrome, atypical
(second-generation) antipsychotics 62, 68
metabolites, generic drugs 47
methylphenidate, concepts 47, 109–14
MHRA see Medicines and Healthcare Products
Regulatory Agency
Miltown see meprobamate
the mind, concepts 15–17
minimalist approaches to medicine 123
mirtazapine
see also tetracyclines
concepts 93, 100–2
modafanil, concepts 110
Moncrieff, Joanna 160–1
monoamine oxidase inhibitors (MAOIs)
see also antidepressants
concepts 7, 90–1
monoamines
see also dopamine; norepinephrine; serotonin
concepts 12–17, 128
monotherapy comparisons, polypharmacy 127–8
mood disorders 64–7, 69, 134, 136, 146–7, 155–63
mood instability see affective instability
mood stabilizers
see also anticonvulsant . . .; antidepressants;
antimanicis; bipolar disorder; lithium
concepts 7, 38, 50–1, 64–8, 69–84, 119–20, 125–6, 128, 155–63
critique 77–84, 158
definition 69–70
depression 126
follow-up studies 71–3
historical background 7
indications 70–3
meta-analyses 71–2
recurrence-prevention issues 69–84, 161
side effects 7, 10, 70–84, 120
moodiness distinctions
bipolar disorder 74–5, 77–8, 82–4
childhood depression 115
moralizing attitudes, medicalization of distress 146–7
mortality rates, schizophrenia 61, 62
Mosher, Lorne 159
multiple-drug treatments
see also polypharmacy
concepts 30, 53–4, 123–30, 141–2, 156, 162–3
critique 68, 123–30
INDEX 203

National Comorbidity Survey (NCS) 87, 145, 151
National Institute for Clinical Excellence (NICE) 29, 57, 69, 103, 107, 111–12, 116–17, 133–5, 138, 156
National Institute of Mental Health (NIMH) 33, 37–8, 72, 99–102, 134–5
Nature 36–7
NCS see National Comorbidity Survey
NE see norepinephrine
negative symptoms, schizophrenia 57–68, 157–8
Nemeroff, Charles 36–7
neuroleptic malignant syndrome (NMS) 58–9
neuroleptics 5, 8, 10, 13–14, 38, 50–1, 57–68, 88, 101–2, 125–6, 128, 158, 161 see also antipsychotics
critique 57–68, 158, 161
effectiveness 8, 10, 13–14, 57–68, 88
historical background 5, 8, 10
neurons, concepts 11–12, 114–15, 127–8, 139–40, 153, 155–6, 158–9
Neuropsychopharmacology 37
neuroscience, concepts 8, 11–12, 15–16, 133–4, 139–40, 153, 155–6, 158–9
neuroticism, concepts 85
neurotransmitters, concepts 11–17, 92–3, 114–15, 127–8, 139–40, 158–9
new drugs 10, 15, 31–54, 90–107, 156–8 see also pharmaceutical industry
approval processes 33–4, 41–2
costs 156–8
existing drugs 8, 46–7, 53–4, 90–1, 156–8
future prospects 156–8
marketing tactics 10, 15, 45–50
prices 53–4
The New York Times 36–8, 50
New Zealand 49
NHS, CBT provisions 137, 138
NICE see National Institute for Clinical Excellence
NIMH see National Institute of Mental Health
NMDA (N-methyl D-aspartate) receptor 13–17
NNH see number needed to harm
NNT see number needed to treat
non-compliance 6, 61
non-SSRI antidepressants, concepts 92–3
noradrenergic system 14
norepinephrine (NE), concepts 12–17, 92–3
normalization of mental illness see also medicalization of distress
definition 144
nortriptyline, concepts 100–2
number needed to harm (NNH), concepts 27–8
number needed to treat (NNT), concepts 27–8
obsessive-compulsive disorder (OCD) see also anxiety
antidepressants 14, 85, 105–6
concepts 14, 85, 105–6
treatments 14, 85, 105–6
off-label approaches
antipsychotics 57–8, 61–2, 66, 68, 69, 163
concepts 30, 57–8, 61–2, 66, 68, 69, 148, 163
regulations 58, 148
olanzapine, concepts 61–2, 63–4, 67
Olivieri, Nancy 40
open trials, critique 23, 25, 68
oppositional defiant disorder, concepts 117–20
Osheroff, Raphael 9
Osler, William (1856–1919) 22, 46, 123, 147–8
out-patient management 5, 58–9
panic attacks
concepts 19, 85, 106
diagnoses 19
treatments 19, 85, 106
paraldehyde 5
paranoid schizophrenia, concepts 4, 20
parent training, concepts 120–1
paroxetine, concepts 92–3
penicillin 11
perphenazine 63–4
personality disorders
ADHD 113–14
bipolar disorder 79, 82–3
definition 79, 151
prevalence 151
treatments 80, 125–6, 134, 135, 136, 150, 157–8
pharmaceutical industry
academic psychiatry 31–40, 42–4
advertisements 45–7, 49–50, 66
APA influences 35–6, 52
background 31–54
cognitive biases 33, 36
corruption allegations 34–5, 36–7
pharmaceutical industry (Cont.)
diagnosis issues 50–4
‘disease mongering’ allegations 143–4
fees 34–41, 44–5, 48–9, 52–4
generic drugs 47, 62, 66
ghostwriting concerns 34–5
gifts to physicians 48–9, 54
Grassley’s investigations 35–8
industry-funded research 24–5, 28, 29–30, 32–42, 46–7, 52–4
integrity threats to clinical trials 40–4
limits of power 42–4
marketing tactics 10, 15, 45–50, 66–8
media pressures 35–9, 95
medicalization of distress 143–4, 146–7, 150
new mental disorders 50–4, 150
political influences 32, 35–6, 49–50
prescription decisions 31–54
profits 31–2, 32, 34–5, 67, 137, 143–4, 157
psychiatrists 44–7, 48–9, 146–7
representatives (salespeople) 46–7
suppression of negative findings 40–3, 45–6, 94
USA 32–4, 41, 48–54
pharmacological dissection, concepts 19
phenomenological approach, diagnoses 18, 83
phenothiazine
see also antipsychotics; chlorpromazine;
piperazines; piperidines
concepts 6, 8, 58–60, 64, 155
historical background 6, 8, 58–60
side effects 58–9, 60, 64
piperazines
see also antipsychotics; phenothiazine
concepts 59–60, 64
piperidines
see also antipsychotics; phenothiazine
concepts 59–60
placebo effects
concepts 28, 90, 94–7, 100–2, 114, 115, 125, 129, 161
meta-analyses 94–5
polypharmacy 125, 129
placebos
concepts 3, 24–30, 41–2, 66, 90, 94–7, 100–2, 114, 115, 125, 129, 161
ethics 26
planning, abnormalities 15
plastic surgery 152–3
pneumonia 151–2
political influences
pharmaceutical industry 32, 35–6, 49–50
post-traumatic stress disorder 144
polydipsia 70–1
polypharmacy
see also multiple-drug treatments
concepts 30, 53–4, 123–30, 141–2, 156, 162–3
critique 30, 53–4, 123–30, 152, 156, 162–3
definition 53, 123, 125
good intentions 130
historical background 123
monotherapy comparisons 127–8
placebo effects 125, 129
‘primrose path’ walks 128–9
processes 125–6
rational criteria 126–8
reasons 124–5, 128–30
side effects 53, 123
specialty clinics 125–6
treatment-resistance problems 124–30, 152, 162–3
trends 123–5
polyuria 70–1
positive symptoms, schizophrenia 57–68
post-traumatic stress disorder (PTSD)
see also anxiety
concepts 85, 143–4
medicalization of distress 144
political influences 144
treatments 85
prefrontal lobotomies 5
pregabalin 47
prescription decisions
see also treatments
children and adolescents 52, 77–8, 109–21, 145
ECT 104–5, 133
generic drugs 47, 98
medicalization of distress 51, 143–53, 155–63
off-label approaches 30, 57–8, 62, 68, 69, 148, 163
pharmaceutical industry 31–54, 143–4, 146–7
polypharmacy 30, 53–4, 124–30, 141–2
primary care physicians 9–10, 30, 124–5, 145–6, 151–2
psychotherapy 137–8, 141–2, 159–60
prices of new drugs 53–4
primary care physicians, prescription decisions 9–10, 30, 124–5, 145–6, 151–2
INDEX

‘primrose path’ walks to polypharmacy 128–9
private insurance companies in the USA 145, 149–50
profits
see also fees
pharmaceutical industry 31–2, 46–7, 137, 143–4, 157
psychiatrists 137
prostaglandin system 19
Prozac 28, 43, 48
‘Prozac poopout’ 28
see also placebo effects
psychiatric hospitals, historical background 4
Psychiatric News 145
psychiatrists
conflicts of interest 44–7, 48–9, 52–4
fees 44–5, 48–9, 52–4
gifts 48–9, 54
ideological factors 139–41, 155–6
limitations 129–30, 137–8, 139–41, 145–53, 155–63
medicalization of distress 51, 143–53
pharmaceutical industry 44–7, 48–9, 146–7
practice issues 139–41, 155–6
profits 137
psychotherapy 137–42, 159–60
skills 134, 142, 163
training issues 137, 145, 147–8, 162–3
‘psychiatrization’
see also medicalization of distress
concepts 144
psychiatry
‘antipsychiatry’ 158–62
definition 11
evidence-based approaches 5, 8, 10, 20–30, 133–4, 137–8, 141–2
future prospects 3–4, 10, 155–63
medicalization of distress 51, 143–53, 155–63
reasonable/unreasonable critiques 158–62
science 8, 10, 11–30, 133–4, 139–40, 153, 155–6, 158–9
serendipity 11–12, 157–8
teaching considerations 162–3
psychosis
see also antipsychotics; schizophrenia
causes 10, 13–14
costs 135–6, 141–2
declining trends 133–4, 137–8, 160
depression 89–90, 95–6, 100, 115, 133–42, 159–60
efficacy studies 53–4, 80, 89–90, 95–6, 100, 112, 115, 133–4, 136, 159–60
historical background 5–6, 9
ideological factors 139–41, 155–6
IPT 9, 134
prescription decisions 137–8, 141–2, 159–60
processes 134–5, 136–7
psychiatrists 137–42
referrals 137–8, 142, 162
regulations 138–9
relapse benefits 135
suitable patients 135, 136–7
timescales 134, 135–6, 141–2
PTSD see post-traumatic stress disorder
public funding needs, clinical trials 42
quetiapine
concepts 47, 61–2, 63–4, 66–8
popularity 68
rage 147, 151
randomized clinical trials (RCTs)
see also evidence-based medicine
INDEX

randomized clinical trials (RCTs) (Cont.)
absolute/relative risk measures 27, 41
approval processes 33–4, 41–2
concepts 8, 21–30, 83, 85, 96–7, 101–4, 161–2
conduct 25–8
costs 24–5
critique 23–8
dropouts 24, 67
effect sizes 27–8, 98
follow-ups 24, 67
historical background 8, 21–3
industry-funded RCTs 24–5, 28, 29–30,
32–42, 46–7, 52–4
integrity threats 40–4
manipulated results 40–1, 42–4, 45–6
NNT/NNH statistics 27–8
Phases 26–7
placebo effects 28
public funding needs 42
regulation 33, 37–8, 40–2, 53, 54
reporting systems 40–1, 53–4
secondary analyses 41
statistical analysis/interpretation of results
27–8, 41–3, 94–5
suppression of negative findings 40–3, 45–6,
94
timescales 24–5
receptors in the brain, concepts 11–17, 92–3,
114–16, 127–8, 139–40, 153, 155–6
recurrence-prevention issues
antidepressants 90, 161
mood stabilizers 69–84, 161
reductionist psychiatry 140, 153
references 165–93
referrals, psychotherapy 137–8, 142, 162
refugees, medicalization of distress 144
regulations
approval processes for new drugs 33–4, 41–2,
53, 54
clinical trials 33, 37–8, 40–2, 53, 54
FDA 41, 62, 66, 71–2, 103–4, 148
gifts to physicians 48–9, 54
off-label approaches 58, 148
psychotherapy 138–9
reporting systems 40–1, 53–4
relapse issues
antidepressants 95–7
psychotherapy 135
religion 143
remission of illness
optimistic approaches 128–9
RCTs 24
reporting systems, clinical trials 40–1, 53–4
representatives (salespeople), pharmaceutical
industry 46–7
research findings
see also randomized clinical trials
clinical guidelines 29–30, 68
critique 22–3, 25, 29–30, 40–2, 148–9
integrity threats to clinical trials 40–4
restlessness 88
revolution in the early 1950’s, history of
psychopharmacology 4–10
risperidone, concepts 61–2, 63–4
sadness 147, 152
sampling, concepts 22–30, 40–2
Schatzberg, Alan 36
schizophrenia 4, 5, 6–7, 10, 13, 19, 20, 26,
57–68, 73, 75, 81, 119–20, 125–6, 134, 146,
157, 159–60
see also antipsychotics; delusions;
hallucinations; psychosis
bipolar disorder 73, 75
causes 10, 13–14
diagnoses 19, 75
mortality rates 61, 62
onset 119–20
suicide attempts 61
symptoms 4, 57–68, 75
talking therapies 8, 159–60
treatment-resistance problems 10, 60–1, 66–7
treatments 5, 6–7, 8–9, 10, 13, 20, 26, 57–68,
125–6, 134, 157, 159–60
Schou, Mogens (1918–2005) 7
the science of psychopharmacology 8, 10, 11–30,
133–4, 139–40, 153, 155–6, 158–9
secondary analyses, clinical trials 41
sedatives 6, 8, 13, 58–68, 83, 93, 120, 158, 161
selection bias, concepts 20
self concepts, ‘cultural narcissism’ 153
self-harm, concepts 115–16
serendipity, psychopharmacology 11–12, 157–8
serotonin (5-HT), concepts 12–17, 91–3
sertraline, concepts 92–3, 97–8, 99–102
service delivery, medicalization of distress 153
severe mood dysregulation (SMD)
see also bipolar disorder
concept 119
sexual side effects, antidepressants 92–3
SGAs see atypical (second-generation)
antipsychotics
side effects
advertisements 45–6
antidepressants 90–107
antipsychotics 58–68, 120
treatment-resistance problems 9–10, 19, 28, 60–1, 66–7, 98–103, 124–30, 152, 162–3
see also polypharmacy

tricyclics

see also antidepressants; imipramine; specific serotonin reuptake inhibitors
effectiveness 9, 90–2, 103–4, 105–6, 156
historical background 7, 8, 9, 90, 106, 107, 113–14, 120–1, 147, 152, 155–63
typical see first-generation antipsychotics

unhappiness distinctions, depression 87–8, 143–4, 147, 152–3, 155
unitary theory of depression 89–90
USA 17–18, 29, 35–6, 48–54, 63, 75, 90, 102, 111–12, 124, 137–9, 145–6, 148, 149–51, 156
vagus nerve stimulation 37
Valium see diazepam

weight-gain/loss problems, concepts 62, 86–7, 120
Withering, William (1741–1799) 11
World Health Organization 18, 86
World Psychiatric Association 35
worried-well market 31–2, 153

Ypsilanti State Hospital 4, 9
ziprasidone, concepts 62, 63–4

Index compiled by Terry Halliday